Ce qui a changé
Opérations et participationsDeux dirigeants de Takeda Pharmaceutical Co Ltd ont déclaré avoir vendu des actions de la société en novembre 2026. Ces transactions, impliquant les présidents des unités OBU et IBU, ont eu lieu au début du mois.

Ce qui a changéTakeda a publié le 29 octobre ses résultats du premier semestre de l'exercice 2026. Le chiffre d'affaires s'est élevé à 2 407,0 milliards de yens, en hausse de 8,4 % aux taux de change réels, mais en baisse de 1,0 % à taux de change constants. Le groupe a également révisé ses prévisions pour l'exercice clos en mars 2027.

Ce qui a changéTakeda said that on September 14, 2026, the FDA and the European Medicines Agency (EMA) accepted applications for zasocitinib (TAK‑279) to treat moderate-to-severe plaque psoriasis, opening the way to further regulatory review.

Historique de la société
Octobre 2026
TAKEDA PHARMACEUTICAL CO LTD: 12 recorded developments from 2 official sources in 2026-10.
- 2026-10-29: Amortization and impairment losses on intangible assets associated with products were 218.5 billion JPY in the six-month period ended September 30, 2026, down 35.1% at actual exchange rates. Source
- 2026-10-29: Other operating expenses rose mainly because restructuring expenses increased by 52.4 billion JPY, reflecting the ongoing implementation of the transformation program. Source
- 2026-10-29: Income tax expenses were 13.0 billion JPY, mainly due to deferred tax benefits from a reassessment of the recoverability of deferred tax assets. Source
- 2026-10-29: In GI, sales in the United States were 351.8 billion JPY, up 10.3% at actual exchange rates, driven by favorable exchange rates against the U.S. dollar and growth of the subcutaneous formulation. Source
- 2026-10-29: In GI, sales in Europe were 124.9 billion JPY, up 15.1% at actual exchange rates, due to favorable exchange rates against the euro and continued growth in patient numbers. Source
- 2026-10-29: TRINTELLIX sales were 71.3 billion JPY, up 25.2% at actual exchange rates, mainly due to pricing favorability in the U.S., including a price increase and shifts in payer mix. Source
- 2026-10-29: Net finance expenses rose to 88.0 billion JPY, mainly due to higher interest on the U.S. dollar senior guaranteed notes issued July 2, 2025, a building lease liability, and losses on investments in convertible notes. Source
- 2026-10-29: Core operating profit in FY2026 H1 was 710.6 billion JPY, up 11.2% at actual exchange rates and 0.7% at constant exchange rates. Source
- 2026-10-29: Revenue for the six months ended September 30, 2026 was 2,406,997 million JPY, up 8.4% from the same period a year earlier. Source
- 2026-10-29: Net profit attributable to owners of the Company for the six months ended September 30, 2026 was 305,626 million JPY, up 171.8%. Source
- 2026-10-29: Forecast revenue for the fiscal year ending March 31, 2027 is 4,700,000 million JPY, up 4.3% from the previous fiscal year. Source
- 2026-10-29: Management guidance for the fiscal year ending March 31, 2027 on a constant exchange rate basis: core revenue growth low-single digit % decline, core operating profit mid-single digit % decline, core EPS low-teens % decline. Source
Septembre 2026
TAKEDA PHARMACEUTICAL CO LTD: 12 recorded developments from 1 official source in 2026-09.
- 2026-09-14: FDA accepted Takeda's New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Source
- 2026-09-14: Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. Source
- 2026-09-14: Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. Source
- 2026-09-14: In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Source
- 2026-09-14: This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or ot Source
- 2026-09-14: The European Medicines Agency (EMA) also accepted Takeda's new marketing authorization application (MAA) for zasocitinib, initiating the review process for the treatment of moderate-to-severe plaque psoriasis. Source
- 2026-09-14: Takeda plans to submit additional applications for plaque psoriasis with global regulatory authorities to bring zasocitinib to people living with psoriasis worldwide. Source
- 2026-09-14: Zasocitinib is an investigational, next-generation, highly selective and potent oral TYK2 inhibitor that maintains 24-hour inhibition of IL-23 plus other core disease-driving immune pathways. It has the potential to be a leading oral treatment option for people living with psoriasis that Source
- 2026-09-14: Zasocitinib has more than 1-million-fold greater selectivity for TYK2 compared to other JAK enzymes, which could maximize TYK2 inhibition without impacting JAK1, 2 and 3 signaling, based on in vitro data. Source
- 2026-09-14: Takeda is currently evaluating the safety and efficacy of zasocitinib in Phase 3 studies in psoriatic arthritis and Phase 2 studies in Crohn’s disease, ulcerative colitis, vitiligo and hidradenitis suppurativa. Source
- 2026-09-14: The co-primary endpoints were the proportion of zasocitinib-treated patients achieving sPGA 0/1 and PASI 75 response compared to placebo at week 16. Ranked secondary endpoints included comparisons versus placebo (week 16) and apremilast (week 16 and week 24). Source
- 2026-09-14: We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Source
Les synthèses mensuelles sont rédigées par l’IA à partir des rapports et sources officielles vérifiés de chaque mois (en anglais, tels qu’extraits), chaque ligne renvoyant à sa source ; les fils conducteurs regroupent les développements liés entre analyses grâce aux embeddings vectoriels (Amazon Titan Text Embeddings V2). Contexte provisoire, pas un conseil en investissement.
Pairs du secteur
Comparaison avec 36 entreprises suivies dans le secteur Santé (variation médiane du CA : +7,2% sur 1 an), d'après les données SEC XBRL.
| Entreprise | Dernier CA | CA sur 1 an | Marge opérationnelle |
|---|
| Takeda Pharmaceutical Co. Ltd TAK | — | — | — |
| Unitedhealth Group Inc UNH | 113 Md $ | -0,4% | 5,8% |
| Mckesson Corp MCK | 111 Md $ | +7,6% | 1,4% |
| CVS Health Corp CVS | 108 Md $ | +5,4% | 3,3% |
| Cigna Group CI | 73,7 Md $ | +5,6% | 3,3% |
| Cardinal Health Inc CAH | 67,5 Md $ | +5,5% | 1,1% |
| Elevance Health, Inc. ELV | 51,4 Md $ | +1,4% | 2,5% |
Dernière période publiée par entreprise selon SEC CompanyFacts (XBRL). Les calendriers fiscaux peuvent différer.
Attentes et réalité
En cours
Forecast core revenue for the fiscal year ending March 31, 2027 is 4,700,000 million JPY, and core operating profit is 1,190,000 million JPY.
Déclaré le 29 octobre 2026 · Période citée : For the Fiscal Year Ending March 31, 2027 · Source · Notre analyse
Évaluation IA, provisoire pas encore d’élément nouveau dans les rapports suivants (au 12 novembre 2026) · Analyse ultérieure
The NDA filing has no significant impact on the full year consolidated financial forecast for the fiscal year ending March 31, 2027.
Déclaré le 14 septembre 2026 · Période citée : fiscal year ending March 31, 2027 · Source · Notre analyse
Évaluation IA, provisoire pas encore d’élément nouveau dans les rapports suivants (au 12 novembre 2026) · Analyse ultérieure
Zasocitinib is currently under FDA Priority Review, with a decision anticipated in the first quarter of 2027. If approved, zasocitinib could become available to appropriate patients after FDA approval.
Déclaré le 14 septembre 2026 · Période citée : first quarter of 2027 · Source · Notre analyse
Évaluation IA, provisoire pas encore d’élément nouveau dans les rapports suivants (au 12 novembre 2026) · Analyse ultérieure
Ce que la direction a annoncé dans les propres documents de l’entreprise (objectifs, projets, prévisions ; en anglais, tel qu’extrait), avec la date et la période citée. Les évaluations sont rédigées par l’IA à partir des rapports suivants : provisoires, non vérifiées par un rédacteur, et un rapport ultérieur cohérent n’est pas une preuve. La décision d’un rédacteur les remplace.
Grands fonds (13F)
D’après les rapports trimestriels 13F-HR des grands fonds que nous suivons, tels que déposés. Les fonds déclarent jusqu’à 45 jours après la fin du trimestre : les positions ont pu changer depuis. Variation : par rapport au trimestre précédent du même fonds. Pas une recommandation.